a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced the voting results for its nominees for director at its reconvened annual and special meeting of shareholders held today.
The director nominees were presented in the Company’s Management Information Circular dated February 25, 2015 and in a press release dated March 25, 2015, and shareholders elected all directors set out in the press release. The directors will serve until the next annual general meeting of the Company. The voting results for the election of each director are as follows:
|Clive J. Beddoe||25,407,705||100%||0||0%|
|Gerald R. Connor||25,407,705||100%||0||0%|
|Wilmot L. Matthews||25,407,705||100%||0||0%|
|Cameron R. Prange||25,407,705||100%||0||0%|
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit www.sqidiagnostics.com.
For further information please contact:
Chief Executive Officer
416.674.9500 ext. 229
Chief Financial Officer
416.674.9500 ext. 241
This news release contains certain forward-looking statements, including, without limitation, statements containing the words “will”, “to be” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.